EUCTR2017-000876-27-GB进行中（未招募）1 期
ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular Myopathy (XLMTM) Patients - ASPIRO
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Subject has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene as assessed by a Sponsor-approved testing facility.
- •2.Subject is male.
- •3.Subject is aged less than 5 years old at Day 1 and/or participated in the ATX MTM 009 (INCEPTUS) study.
- •4.Subject requires mechanical ventilatory support:
- •Part 1: Subject requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full time mechanical ventilation, to noninvasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours).
- •Part 2: Subject requires invasive mechanical ventilatory support ranging from 20 - 24 hours per day at screening (confirmed by daytime polysomnographic study).
- •5.Subject requiring invasive mechanical ventilator support is fitted with or willing to be fitted with a cuffed tracheostomy tube for some respiratory assessments.
- •6.Subject has ventilator maximum positive end-expiratory pressure (PEEP) < 8 cm H2O at screening.
- •7.Signed informed consent by the parent(s) or legally authorized representative(s) (LAR) (when applicable).
- •8. Subject and parent(s)/LAR(s) are willing and able to comply with study visits and study procedures.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Subject is participating in an interventional study designed to treat XLMTM.
- •2.Subject born <35 weeks gestation who is still not term as per corrected age.
- •3.Subject tests positive for AAV8 neutralizing antibody with titers > 1:20 (subjects under the age of 18 months may be retested in cases where antibodies may have been maternally acquired and titers may decline in the first months of life).
- •4.Subject had recent surgery (< 3 months before Day 1) or has planned surgery that may confound data collection during the first 48 weeks of the study.
- •5.Subject has a clinically important condition or life-threatening disease, other than XLMTM, in the opinion of the investigator.
- •6.Subject has a clinically significant underlying liver disease, defined as:
- •= Grade 3 Aspartate aminotransferase (> 5.0 x upper limit of normal
- •[ULN]) [CTCAE v. 4.03]
- •= Grade 3 Alanine aminotransferase (> 5.0 x ULN) [CTCAE v. 4.03] Hepatic peliosis or any other clinically significant structural abnormality detected by ultrasound
- •7.Subject is currently experiencing a clinically important respiratory infection or other active infection.
- •8.Subject has received pyridostigmine or any medication to treat XLMTM within 3 months before Day 1.
- •9.Other than as required per protocol, subject has received immune-modulating agents within 3 months before Day 1 (use of inhaled corticosteroids to manage chronic respiratory conditions is allowed); use of other concomitant medications to manage chronic conditions must have been stable for at least 4 weeks before dosing.
- •10.Subject has a contraindication to prednisolone.
- •11.Subject has a contraindication to study drug or ingredients.
- •12.Subject has previous scoliosis repair surgery/procedure, or planned/expected scoliosis repair surgery/procedure in the 12 months following Day 1 (Part 2 only).
- •13.Subject has contractures, scoliosis, or other medical condition that would limit the potential to achieve unassisted sitting, in the opinion of the investigator (Part 2 only).
- •14.Subject is able to sit without assistance for at least 30 seconds at screening, in the opinion of the investigator (Part 2 only).
- •15.Subject has a clinically important condition, including Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade = 2 anemia (< 10g/dL hemoglobin)
研究者
相似试验
进行中（未招募）
1 期
First-in-human study of AT132 in X-Linked Myotubular Myopathy (XLMTM) PatientsX-linked Myotubular Myopathy (XLMTM)EUCTR2017-000876-27-FRAudentes Therapeutics Inc.12
招募中
1 期
First-in-human study of AT132 in X-Linked Myotubular Myopathy (XLMTM) PatientsX-linked Myotubular Myopathy (XLMTM)MedDRA version: 20.0Level: HLGTClassification code: 10029317Term: Neuromuscular disorders Class: 10029205CTIS2024-512637-32-00Astellas Gene Therapies Inc.26
招募中
3 期
First-in-human study of AT132 in X-Linked Myotubular Myopathy (XLMTM) Patients2024-512637-32-00Astellas Gene Therapies Inc.5
招募中
2 期
Phase II, Open-label, Randomized, Multiple Ascending Dose Confirmation of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney TransplantatioBK virus infection (viremia) after kidney transplantationJPRN-jRCT2041220056Hoshino Yuji36
进行中（未招募）
不适用
A phase II study, performed over a period of approximately 20 months,at one study site in Colombia in a population of subjects 18 to 40 years of age. Its aim was to evaluate the immunogenicity, safety and tolerability of H5N1adjuvanted vaccine given either sequentially, concomitantly or usingextemporaneous mixing with a seasonal trivalent influenza vaccine (Agrippal).InfluenzaEUCTR2014-004515-37-Outside-EU/EEAovartis Vaccines and Diagnostics400